SCHEMBL6077530

SCHEMBL6077530

Fc1ccc(-c2c[nH]nc2-c2ccncc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.53
MAPK10 P53779 1/20 0.53
MAPK13 O15264 6/20 0.53
MAPK12 P53778 6/20 0.53
MAPK11 Q15759 6/20 0.53
GCGR P47871 6/20 0.51
CSNK1D P48730 3/20 0.50
CSNK1E P49674 2/20 0.50
MAPK9 P45984 2/20 0.49
RAF1 P04049 1/20 0.49
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
FRK P42685 1/20 0.47
CSNK1A1 P48729 1/20 0.47
GSK3B P49841 1/20 0.47
PTK6 Q13882 1/20 0.47
PRKD2 Q9BZL6 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
ALOX5 P09917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1554633 1.00 MAPK14 (0.53) MAPK14MAPK10MAPK13MAPK12MAPK11
Hydrochloric Acid SCHEMBL1554763 0.98 MAPK14 (0.51) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL5451902 0.89 IMPDH2 (0.44) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL28329372 0.86 ADORA1 (0.49) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL5256518 0.84 NOTUM (0.52) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL5541099 0.83 KIF11 (0.56) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL5457022 0.83 MAPK14 (0.43) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL5256520 0.83 GCGR (0.49) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL15022262 0.83 MAPK14 (0.47) MAPK14MAPK10MAPK13MAPK12MAPK11
SCHEMBL6078860 0.83 GCGR (0.49) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019005-B2 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors G. D. SEARLE & CO. (US) 2006-03-28 US claimed
US-20040147579-A1 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors PHARMACIA CORPORATION 2004-07-29 US claimed
US-20020086869-A1 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors PHARMACIA CORPORATION 2002-07-04 US claimed
US-6335336-B1 TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE G.D. SEARLE & COMPANY 2002-01-01 US claimed
CN-1264376-A 3(5)-Heteroaryl substituted pyrazoles as P38 kinase inhibitors SEARLE & CO (US) 2000-08-23 CN claimed
US-6087496-A ENZYME INHIBITORS G. D. SEARLE & CO. (US) 2000-07-11 US claimed
EP-0983260-A2 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. Searle & Co. (US) 2000-03-08 EP claimed
WO-1998052937-A2 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE G.D. SEARLE AND CO. (US) 1998-11-26 WO claimed
US-7019005-B2 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors G. D. SEARLE & CO. (US) 2006-03-28 US disclosed
US-20040147579-A1 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors PHARMACIA CORPORATION 2004-07-29 US disclosed
US-6579873-B2 Treatment of inflammation, arthritis, bone disorders, respiratory system disorders PHARMACIA CORPORATION 2003-06-17 US disclosed
US-20020086869-A1 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors PHARMACIA CORPORATION 2002-07-04 US disclosed
US-6335336-B1 TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE G.D. SEARLE & COMPANY 2002-01-01 US disclosed
CN-1264376-A 3(5)-Heteroaryl substituted pyrazoles as P38 kinase inhibitors SEARLE & CO (US) 2000-08-23 CN disclosed
US-6087496-A ENZYME INHIBITORS G. D. SEARLE & CO. (US) 2000-07-11 US disclosed
EP-0983260-A2 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS G.D. Searle & Co. (US) 2000-03-08 EP disclosed
WO-1998052937-A2 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE G.D. SEARLE AND CO. (US) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147579-A1 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors MAPK1, MAPKAPK2, MAPK3 MAPK14 26/4885MAPK10 40/4885MAPK13 28/4885
US-20020086869-A1 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors MAPK1, MAPKAPK2, MAPK3 MAPK14 26/4885MAPK10 40/4885MAPK13 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.